Aneesha Mathur | New Delhi
Anti-diabetes drugs, Zita and Zitamet, are set to go off the market in two weeks, with the Delhi High Court on Friday issuing an injunction against generic drug manufacturer Glenmark on a patent infringement suit filed by US-based drug major Merck Sharp and Dohme (MSD).
The court of Justice S Ravindra Bhat and Justice Najmi Waziri issued the injunction, directing Glenmark to stop supply of the drugs. While, Glenmark can sell the products that are already with distributors and retailers, it is not allowed to put any further products on the market.
The court, in its 81 page order, however, held that prima facie, MSD had been able to show patent infringement, but has noted that the final decision on the issue of patent rights could only be taken after proper trial.
Source: Indian Express
Comments are closed.